Reyataz and Hypercalcaemia - a phase IV clinical study of FDA data

Summary:

Hypercalcaemia is reported as a side effect among people who take Reyataz (atazanavir sulfate), especially for people who are female, 50-59 old, have been taking the drug for 1 - 6 months also take Norvir, and have Osteoporosis.

The phase IV clinical study analyzes which people have Hypercalcaemia when taking Reyataz. It is created by eHealthMe based on reports of 11,228 people who have side effects when taking Reyataz from the FDA, and is updated regularly.

What is Reyataz?

Reyataz has active ingredients of atazanavir sulfate. It is often used in hiv infection. eHealthMe is studying from 11,386 Reyataz users. Check the latest studies of Reyataz.

What is Hypercalcaemia?

Hypercalcaemia (elevated calcium (ca+) level in the blood) is found to be associated with 1,057 drugs and 1,018 conditions by eHealthMe. Check the latest studies of Hypercalcaemia.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 21, 2026

11,228 people reported to have side effects when taking Reyataz.
Among them, 14 people (0.12%) have Hypercalcaemia.

Among these 14 people:

How long have people been on Reyataz when they have Hypercalcaemia? *

What is the gender of people who have Hypercalcaemia when taking Reyataz? *

female: 61.54 %
male: 38.46 %

What is the age of people who have Hypercalcaemia when taking Reyataz? *

What are other drugs people take besides Reyataz? *

What are other side effects people have besides Hypercalcaemia? *

Acute Kidney Failure: 9 people, 64.29%
Chronic Kidney Disease: 7 people, 50.00%
Emotional Distress: 7 people, 50.00%
Mobility Decreased (ability to move is reduced): 5 people, 35.71%
Anaemia (lack of blood): 5 people, 35.71%
Aseptic Necrosis (the death of bone tissue due to a lack of blood supply): 5 people, 35.71%
Bone Loss: 5 people, 35.71%
Gait Disturbance: 5 people, 35.71%
Glomerulosclerosis (a hardening of the glomerulus in the kidney): 5 people, 35.71%
Hyperthyroidism (over activity of the thyroid gland): 5 people, 35.71%

What are the existing conditions these people have? *

Swallowing Difficulty: 2 people, 14.29%
Osteoporosis (bones weak and more likely to break): 2 people, 14.29%
Stress And Anxiety: 1 person, 7.14%
Schizophrenia (a mental disorder characterized by a breakdown of thought processes): 1 person, 7.14%
Rickets (softening of bones): 1 person, 7.14%
Migraine (headache): 1 person, 7.14%
High Blood Pressure: 1 person, 7.14%
Gallbladder Disease: 1 person, 7.14%
Dyslipidaemia (abnormal amount of lipids): 1 person, 7.14%
Drug Dependence: 1 person, 7.14%

* Approximation only. Some reports may have incomplete information.

Do you take Reyataz and have Hypercalcaemia?

- Check whether Hypercalcaemia is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Reyataz:

Reyataz (11,386 reports)

Hypercalcaemia treatments and more:

Hypercalcaemia (18,731 reports)

Browse all side effects of Reyataz:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hypercalcaemia:

Hypercalcaemia (1,057 drugs)

Browse all the conditions that are associated with Hypercalcaemia:

Hypercalcaemia (1,018 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on atazanavir sulfate (the active ingredients of Reyataz) and Reyataz (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.